Navigation Links
New influenza vaccine takes weeks to mass produce

Using cell-based methods researchers have developed a commercially viable method for mass producing effective vaccines against potential pandemic influenza strains in weeks instead of the months required for traditional egg-based vaccines. They report their results today at the 2006 ASM Biodefense Research

The next flu pandemic could happen any time," says Keyang Wang, a scientist at Protein Sciences Corporation (PSC) and a researcher on the study. "The most effective method to control such an outbreak is the widespread use of a vaccine, preferably in a pro-active manner, so that the immune system is primed prior to actual virus exposure. The traditional egg-based method requires 3 to 6 months to develop the vaccine. With our cell-based method, as soon as the pandemic strain is identified, a matched vaccine can be massively produced within 4 weeks."

The vaccine strategy pursued by Protein Sciences, known commercially as FluBlok, uses a purified protein from the surface of the virus called hemagglutinin (the H part of a virus' designation, like H5N1 for the current avian influenza) to elicit an immune response to a specific strain of influenza. The protein is produced by first extracting the genes responsible for the production of hemagglutinin from the influenza virus and inserting them into a baculovirus. Specific host cells are then infected with the baculovirus and produce recombinant hemagglutinin (rHA). Phase II clinical trials show that rHA-based vaccines produced using this system are safe, elicit immunity equal to or greater than egg-based vaccines, and are 100% effective in the prevention of cell culture confirmed influenza.

Wang and his colleagues report the successful production of rHA from 4 strains of influenza that scientists believe to be likely the cause of the next pandemic (H5, H7, H9, and H2) at a level where manufacturing costs are expected to be equal to or less than that of traditional egg-based vaccines.

"It has been suggested that the next pandemic strain may be derived from H5, H7, H9 or H2 influenza viruses. The preparation of the recombinant baculoviruses for the production of these antigens and the successful purifications gives us a great advantage in fighting against a potential influenza pandemic, if it derived from any of these strains," says Wang. "Starting from a stocked recombinant baculovirus bank, a closely matched vaccine can be massively produced within 2 weeks."

PSC has recently signed a Letter of Intent which will support commercial scale manufacturing with the capacity to produce 6 Million doses of monovalent pandemic vaccine per week.


'"/>

Source:American Society for Microbiology


Related biology news :

1. Computers to be used to find blueprint for new influenza drug
2. Less virulent strains of avian influenza can infect humans
3. Drug resistant avian influenza viruses more common in Southeast Asia than North America
4. New vaccine platform may fight infections with causes from influenza to bioterrorism
5. First big influenza genome study reveals flu evolution
6. Web model of influenza-host lifecycles will aid scientists in creating anti-viral drugs
7. Study outlines genetic differences between potential pandemic influenza strains
8. Avian influenza virus in mammals spreads beyond the site of infection to other organ systems
9. How can we protect patients with weakened immune systems from influenza?
10. Mouse study reveals new clues about virulence of 1918 influenza virus
11. Molecular anatomy of influenza virus detailed
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
Breaking Biology Technology: